Eudy Amanda M, Clowse Megan E B, Corneli Amy, Starling Summer, Molokwu Nneka Jebose, Swezey Teresa, Pisetsky David S, Maheswaranathan Mithu, Doss Jayanth, Sun Kai, Sadun Rebecca E, Criscione-Schreiber Lisa G, Rogers Jennifer L
Duke University School of Medicine, Durham, North Carolina.
Duke University School of Medicine and Durham Veterans Affairs Medical Center, Durham, North Carolina.
ACR Open Rheumatol. 2024 Dec;6(12):865-870. doi: 10.1002/acr2.11748. Epub 2024 Sep 29.
The Type 1 and 2 systemic lupus erythematosus (SLE) Model was developed to encapsulate all signs and symptoms that patients with SLE experience. Our previous qualitative work demonstrated the model accurately reflects the lived experience of people living with SLE. The objective of this study was to present the Type 1 and 2 SLE Model to rheumatologists to understand how the model fits with their experiences treating patients with SLE.
We conducted a qualitative descriptive study using semistructured interviews with rheumatologists. Rheumatologists were asked about their general impression of the Type 1 and 2 SLE Model, how the model does or does not fit within their approach to treating patients with SLE, the utility of the model in clinical practice, and any suggested changes. Applied thematic analysis identified salient themes.
We interviewed 13 rheumatologists. The majority of rheumatologists approved of the model and found it useful to guide therapy and clinical decision-making. Several rheumatologists thought the model was helpful for patient education to manage expectations about differences between Type 1 and Type 2 symptoms and treatments. A few rheumatologists expressed concern that the model could lead to an overdiagnosis of SLE.
The Type 1 and 2 SLE Model was accepted by most rheumatologists interviewed and welcomed as a useful approach to identifying and treating symptoms in patients with SLE. Future studies will determine how implementing the Type 1 and 2 SLE Model affects patient understanding, the physician-patient relationship, and clinical outcomes.
开发1型和2型系统性红斑狼疮（SLE）模型，以囊括SLE患者所经历的所有体征和症状。我们之前的定性研究表明，该模型准确反映了SLE患者的实际生活体验。本研究的目的是向风湿病学家展示1型和2型SLE模型，以了解该模型与他们治疗SLE患者的经验契合程度。
我们采用对风湿病学家进行半结构化访谈的方式开展了一项定性描述性研究。询问风湿病学家对1型和2型SLE模型的总体印象、该模型在他们治疗SLE患者的方法中是否适用、该模型在临床实践中的实用性以及任何建议的改进。应用主题分析法确定突出主题。
我们采访了13名风湿病学家。大多数风湿病学家认可该模型，并认为它有助于指导治疗和临床决策。几位风湿病学家认为该模型有助于患者教育，以管理对1型和2型症状及治疗差异的预期。少数风湿病学家担心该模型可能导致SLE的过度诊断。
接受访谈的大多数风湿病学家认可1型和2型SLE模型，并欢迎将其作为识别和治疗SLE患者症状的有用方法。未来的研究将确定实施1型和2型SLE模型如何影响患者的理解、医患关系和临床结果。
